"Weitao Bio" Series A financing exceeds $50 million, preliminary human data published for in vivo CAR-T with LNP route
Weitai Bio, a company spun out from Shalier Bio, has secured over $50 million in Series A and A+ funding. The company is advancing its lead drug candidate, GT801, which utilizes a lipid nanoparticle (LNP) delivery system for in vivo CAR-T therapy. Preliminary human data presented at the AACR annual meeting showed GT801 effectively cleared B cells in patients with hematological malignancies and autoimmune diseases, demonstrating the feasibility of repeat dosing. AI
IMPACT Advances in in vivo CAR-T therapy using LNP delivery could accelerate development for autoimmune diseases and certain cancers.
